China News Service, Beijing, June 17th (Reporter Li Yanan) "At present, foreign and domestically-listed clinical and urgently needed imported drugs and device products have been listed abroad. Hainan can not only approve the import and use of Boao Lecheng by itself, but the actual usage data can also Formal clinical data, through research design, data collection, information processing, statistical analysis and multi-dimensional results evaluation, is used as the basis for the future registration and approval of pharmaceutical products in the country, which can accelerate the registration and listing process of innovative pharmaceutical devices in China." Boao Lecheng International Medical Gu Gang, director of the Tourism Pioneer District Administration, said.

  Gu Gang recently received an online interview with reporters to introduce the new progress of Lecheng's imported innovative drugs. He said that the implementation of special policies has greatly promoted the accelerated listing of innovative drugs, which has compressed at least 9 months to 1 year. "Everything is centered on the needs of patients. In response to urgent medical needs, we will launch the Pioneer District Administration and the Lecheng Drug Administration to coordinate relevant companies and departments to help patients choose medicines worldwide. As long as they are internationally leading, in the United States, Innovative drugs registered in the European Union, Japan and other countries can be applied for use in Lecheng. We mainly select drugs based on patient needs and manufacturers' recommendations to implement in Lecheng."

  Gu Gang said, "If a doctor, patient or manufacturer applies for a new drug, a selection meeting will be held when the first case is used. The Provincial Drug Administration will organize relevant experts to review this drug. After the approval is completed, this new drug can be Imported by the agent into the bonded warehouse, when the patient comes to Boao for medical treatment, it can be used according to the patient's condition. In the subsequent use process, there is no need to hold a selection meeting, and the electronic approval form can ensure that the patient can use the innovative drug again. "

  Taking the treatment of atopic dermatitis as an example, this is a refractory, recurrent, systemic skin disease, with severe itching and rash as the main clinical manifestations. Especially for moderate to severe patients, the quality of life is severely affected. In response to the urgent treatment needs of patients, with the help of special medical policies in the leading area, Boao Super Hospital introduced the internationally leading "dual target" biological agent duplizumab in 2019, and the symptoms of many patients who used this drug were obvious improve.

  Gu Gang said that at present, the first use of imported licensed medical devices in the Boao Lecheng International Medical Tourism Pilot Zone of Hainan Free Trade Port has reached 100 cases, and 100 new anti-tumor drugs and rare disease drugs have also been used. At this stage, Lecheng Pioneer District has gathered a group of global innovative medical equipment. The next step is to reduce the price of imported medical equipment. Through the implementation of free trade port policies and measures through super-conventional measures, the introduction of special medicine insurance and other methods to allow domestic patients Can afford international "life-saving medicine". In addition, we will work hard to introduce more innovative medical equipment products, and promote the construction of disciplines for the introduction and use of these innovative drugs, from single diseases to more Lecheng medical solutions, so that more patient needs can be enjoyed The city was resolved to promote the development of clinical science in various disease areas in China, and then promote the development of China's great health cause.

  "Previously, some of the patients' medication needs had to be met abroad. According to incomplete statistics, the number of people who go abroad for medical treatment each year reaches 600,000 to 800,000. Many more patients are limited to economic conditions and cannot go abroad for medical treatment," Gu Gang said. Today, many of them can meet their medication needs in Lecheng.

  Especially when affected by the epidemic, some patients who cannot go abroad for medical treatment urgently need "alternative solutions". Professor Zhang Xuejun, director of the Institute of Dermatology of Huashan Hospital Affiliated to Fudan University and Boao Super Hospital Dermatology Clinical Center, revealed that he has been in the Boao Super Hospital for two years. Due to the impact of the epidemic, the difficult skin registered in the past month or two The number of sick patients has increased significantly compared to the past.

  In order to promote the pilot zone to expand its pilot efforts, the state support policy has been continuously increased in recent years. On February 28, 2013, the State Council officially approved Hainan’s establishment of the Boao Lecheng International Medical Tourism Pioneer Zone, and at the same time issued nine policies, including accelerating the approval of the import registration of medical devices and drugs in the Pioneer Zone, which marked the rise of the Pioneer Zone into a national strategy. The "China (Hainan) Pilot Free Trade Zone Overall Plan" issued in October 2018 proposed that relying on the Boao Lecheng International Medical Tourism Pioneer Zone to vigorously develop international medical tourism and high-end medical services. The “General Plan for the Construction of Hainan Free Trade Port” issued in 2020 once again proposes to enhance the development level of the Boao Lecheng International Medical Tourism Pioneer Zone.

  Recently, the Hainan Free Trade Port Boao Lecheng International Medical Tourism Pilot Zone Regulations were promulgated and implemented. The “Regulations” have been granted to facilitate the diagnosis and treatment of medical personnel and patients at home and abroad, the free and convenient flow of cross-border funds, the tax system, and the improvement of talent development. Corresponding preferential policies. (Finish)